Startups
The new portfolio firm, Ancora Bio, is focused on developing a new drug to address treatment-resistant depression.
The new funding will be used to advance the company’s potential best-in-class epidermal growth factor receptor tyrosine kinase inhibitor furmonertinib, a lung cancer treatment that has been licensed from Allist Pharmaceuticals.
With COVID-19 ducking for cover and going into an almost full retreat across the U.S., Americans are throwing caution – and masks – to the wind. But many are still nervous, and wondering: How do we protect ourselves in this brave new normal?
Life sciences advances continue to be an exciting opportunity for investors. Here’s a glance at the companies attracting fresh funding the past week.
The Third Rock Ventures-backed startup has a pipeline of Treg therapeutics aimed at multiple sclerosis, type 1 diabetes and inclusion body myositis.
Founded in 2014, Insilico focuses on using artificial intelligence for drug discovery and development.
Each week more money pours into the biopharma world. Here’s a peek at who’s getting a taste of fresh funds this week.
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
The new division would benefit from Hahn’s experience and help steer the company’s Preemptive Medicine and Health Security initiative.
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
PRESS RELEASES